300 related articles for article (PubMed ID: 19773417)
1. Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation.
Fangmann J; Arns W; Marti HP; Hauss J; Ketteler M; Beckurts T; Boesmueller C; Pohanka E; Martin PY; Gerhardt M; Farese S; Neumayer HH; Floege J; Gurr C; Budde K;
Nephrol Dial Transplant; 2010 Jan; 25(1):283-92. PubMed ID: 19773417
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.
Ekberg H; Grinyó J; Nashan B; Vanrenterghem Y; Vincenti F; Voulgari A; Truman M; Nasmyth-Miller C; Rashford M
Am J Transplant; 2007 Mar; 7(3):560-70. PubMed ID: 17229079
[TBL] [Abstract][Full Text] [Related]
4. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids.
Tran HTB; Acharya MK; McKay DB; Sayegh MH; Carpenter CB; Auchincloss H; Kirkman RL; Milford EL
J Am Soc Nephrol; 2000 Oct; 11(10):1903-1909. PubMed ID: 11004222
[TBL] [Abstract][Full Text] [Related]
5. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
Abou-Ayache R; Büchler M; Lepogamp P; Westeel PF; Le Meur Y; Etienne I; Lobbedez T; Toupance O; Caillard S; Goujon JM; Bergougnoux L; Touchard G
Nephrol Dial Transplant; 2008 Jun; 23(6):2024-32. PubMed ID: 18199693
[TBL] [Abstract][Full Text] [Related]
6. Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation.
Ekberg H; Persson NH; Källen R; Gül-Baykurt N
Scand J Immunol; 2003 Dec; 58(6):670-7. PubMed ID: 14636424
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation.
Pescovitz MD; Bumgardner G; Gaston RS; Kirkman RL; Light S; Patel IH; Nieforth K; Vincenti F
Clin Transplant; 2003 Dec; 17(6):511-7. PubMed ID: 14756266
[TBL] [Abstract][Full Text] [Related]
8. Is it worth using daclizumab induction therapy with mycophenolate mofetil-based immunosuppressive regimens in live related donor kidney transplantation? A long-term follow up.
Sheashaa HA; Bakr MA; Fouda MA; El-Dahshan KF; Ismail AM; Sobh MA; Ghoneim MA
Int Urol Nephrol; 2007; 39(1):317-9. PubMed ID: 17333530
[TBL] [Abstract][Full Text] [Related]
9. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
[TBL] [Abstract][Full Text] [Related]
10. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.
Ekberg H; Bernasconi C; Tedesco-Silva H; Vítko S; Hugo C; Demirbas A; Acevedo RR; Grinyó J; Frei U; Vanrenterghem Y; Daloze P; Halloran P
Am J Transplant; 2009 Aug; 9(8):1876-85. PubMed ID: 19563339
[TBL] [Abstract][Full Text] [Related]
11. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
Sarwal MM; Vidhun JR; Alexander SR; Satterwhite T; Millan M; Salvatierra O
Transplantation; 2003 Nov; 76(9):1331-9. PubMed ID: 14627912
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
[TBL] [Abstract][Full Text] [Related]
13. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
14. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
[TBL] [Abstract][Full Text] [Related]
15. A prospective randomized study comparing cyclosporine versus tacrolimus combined with daclizumab, mycophenolate mofetil, and steroids in heart transplantation.
Sánchez-Lázaro IJ; Almenar L; Martínez-Dolz L; Buendía-Fuentes F; Agüero J; Navarro-Manchón J; Vicente JL; Salvador A
Clin Transplant; 2011; 25(4):606-13. PubMed ID: 20682020
[TBL] [Abstract][Full Text] [Related]
16. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
[TBL] [Abstract][Full Text] [Related]
17. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients.
Kuypers DR; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
Clin Transplant; 2003 Jun; 17(3):234-41. PubMed ID: 12780674
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
Stratta RJ; Alloway RR; Hodge E; Lo A;
Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
[TBL] [Abstract][Full Text] [Related]
19. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
Kandus A; Grego K; Bren AF
Ther Apher Dial; 2005 Jun; 9(3):262-4. PubMed ID: 15967003
[TBL] [Abstract][Full Text] [Related]
20. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]